-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels: Unique Advantages of the InnoModels Biotechnology CDX Modeling Platform
Author:
InnoModels
Release time:
2024-03-29
With the rapid development of biotechnology, tumor research has ushered in unprecedented opportunities. In this process, animal models play a crucial role as a bridge between basic research and clinical applications. The CDX model platform of InnoModels Biotechnology, with its unique advantages, opens up a new path for tumor research.
1. Highly simulates the human tumor environment
CDX model, i.e. patient-derived xenograft model, is a model that simulates the growth and metastasis of human tumors by implanting tumor cells from patients into experimental animals. By accurately simulating the human tumor environment, InnoModels' CDX model platform provides researchers with a research platform that is extremely close to the real thing. This enables researchers to observe and study the growth, invasion and metastasis of tumor cells in conditions closer to the actual human body, providing more accurate and effective strategies for tumor treatment.
2. Abundant Tumor Cell Resources
InnoModels Biotechnology has more than 500 validated tumor cell lines, which provide researchers with a wide range of choices. Whether it is subcutaneous inoculation, in situ inoculation or systemic inoculation, the CDX model platform can provide flexible and versatile experimental solutions to meet the various needs of researchers for tumor models. In addition, the platform can be used in combination with PBMC humanized immune system reconstructed mice and CD34+HSC humanized immune system humanized mice, which further enhances the realism and practicality of the model.

3、Powerful drug efficacy evaluation capability
An important application of the CDX modeling platform is for drug development and evaluation. By conducting in vivo efficacy experiments on this platform, researchers can visualize the inhibitory effects of drugs on tumor cells and evaluate the efficacy and safety of drugs. The CDX modeling platform of InnoModels Biotechnology has a high success rate and stability, which can ensure the reliability and reproducibility of experimental results. This provides strong support for drug development and helps accelerate the process of new drug development, providing better treatment options for patients.
4、Promote multidisciplinary cooperation and communication
CDX modeling platform is not only applicable to oncology research, but also widely used in immunology, pharmacology, toxicology and other disciplines. This platform provides a platform for researchers from different disciplines to communicate and cooperate, and promotes interdisciplinary research cooperation. Through multidisciplinary cooperation and communication, the mechanisms of tumor occurrence, development and metastasis can be deeply explored, providing new ideas and methods for comprehensive treatment of tumors.
5、Exploration of personalized treatment plan
The CDX model platform also has the potential to explore personalized treatment plans. By implanting patients' tumor cells into experimental animals, researchers can observe the response of tumor cells to different treatment plans, and thus develop personalized treatment plans for patients. This personalized treatment plan can maximize the therapeutic effect, reduce unnecessary side effects, and bring better quality of life to patients.
In conclusion, the CDX model platform of InnoModels Biotechnology has become an important tool in the field of tumor research due to its high simulation of the human tumor environment, rich tumor cell resources, powerful drug efficacy assessment capability, promotion of multidisciplinary cooperation and communication, and potential for exploration of personalized treatment plans. The platform provides researchers with a reliable, practical and efficient research platform for basic tumor research, clinical research and drug development. With the continuous progress and innovation of technology, the CDX model platform will play an even more important role in tumor research and make greater contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd